Create

Sign in to ReadmeX

or

How we handle your data: Privacy Policy

ReadmeX

Your AI reading companion

What would you like to catch up on?

Pick a briefing, or ask your own question.

Your community and people briefings stay personal to you.

Story

Claude designs scorpion toxin binders; 17 of 211 lab-tested designs bind

AI summary

Anthropic says an internal research version of Claude, working inside its Claude Science environment with investment research firm Citrini Research, designed minibinders against five scorpion neurotoxins from four species, generating 318,484 designs in a 64-hour computational phase and selecting 180 candidates; the team added 31 more. Adaptyv Bio and Twist Bioscience tested all 211 designs for binding, and 17 met the team's criteria, covering four of the five toxins, with the strongest candidates binding Cn2 tightly. The reports stress that binding has not been shown to neutralize the toxin, and experts told The Verge the work produced promising starting points but nothing close to a drug. Anthropic released all 211 designs, predicted structures and binding data.

In-depth insight

The experiment is a documented case of a frontier model coordinating literature search, design tools and vendor constraints across a full protein-design workflow, and the full dataset is public for other researchers to check.

**Summary:**As part of our work experimenting with how Claude can help accelerate drug discovery, we asked an internal research model to design minibinders (small proteins that attach tightly to a target) against scorpion neurotoxins. Claude worked from our prompt and four follow-ups, which we developed in collaboration with the financial investment research firm Citrini Research. Teams at Adaptyv Bio and Twist Bioscience experimentally tested 211 designs for binding. Of these, 17 met our criteria. We’re releasing all 211 designs and their data as a resource for the field.

In August, we showed how Claude designed protein minibinders after being given a single prompt. A month before we released those results, a team from Citrini Research had approached us with an interesting question: could Claude (and AI drug discovery more generally) enable a group of motivated nonexperts to tackle a genuine problem in human health? Members of our life science research team set out to answer this, first by brainstorming problems with Claude. We landed on asking for Claude’s help designing novel protein binders against scorpion neurotoxins, with the hope that they could one day be used to develop a scorpion antivenom.

#Anthropic#Claude Science#Citrini Research#Adaptyv Bio#Twist Bioscience

Original · 11 min readRead the original
Group chat

No comments yet. Start the conversation.